zv0203
HER2-positive Advanced Solid Tumor
Hangzhou Adcoris Biopharmacy Co., LtdPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the HER2-positive Advanced Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bnt323 DualityBio Inc. | Phase 1/2 | CCC |
RITONAVIR DualityBio Inc. | Phase 1/2 | CCC |
Trastuzumab Pamirtecan DualityBio Inc. | Phase 1/2 | CCC |
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER DualityBio Inc. | Phase 1/2 | CCC |
Itraconazole DualityBio Inc. | Phase 1/2 | CCC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →